Mesoblast Ltd (MESO) stock surged in the pre-market session as the company skyrocketed +99.77% at 17,72 after the global leader in allogeneic cellular products for inflammation diseases, announced UPBEAT additional results from the DREAM-HF study, an examination of 537 patients with chronic heart failure who were not eligible for rexlemestrocel-L or control sham.
Top 5 EV Tech Stocks to Buy for 2023
According a new report published by BloombergNEF on investment in the energy transition, annual spending on passenger EVs hit $388 billion in 2022, up 53% from the year before. Like we said, the boom is accelerating – and the time to buy EV-related tech stocks is now.
Click Here to Download the FREE Report.
Various clinical studies have demonstrated substantial and durable reductions in heart attacks, strokes, and cardiac deaths following a single dose of rexlemestrocel-L.
This significant improvement may be the first breakthrough in improving outcomes among chronic heart failure patients. These results suggest the New York Heart Association (NYHA) class II HFrEF patients as the best targets for commercialization and registration of rexlemestrocel-L in this large market of heart failure patients.